212 related articles for article (PubMed ID: 11896754)
21. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study.
DeMichele A; Troxel AB; Berlin JA; Weber AL; Bunin GR; Turzo E; Schinnar R; Burgh D; Berlin M; Rubin SC; Rebbeck TR; Strom BL
J Clin Oncol; 2008 Sep; 26(25):4151-9. PubMed ID: 18757329
[TBL] [Abstract][Full Text] [Related]
22. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
Jordan VC
Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
[TBL] [Abstract][Full Text] [Related]
23. Progress in the prevention of breast cancer: concept to reality.
Jordan VC
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
[TBL] [Abstract][Full Text] [Related]
24. Anti-oestrogenic drugs and endometrial cancers.
White IN
Toxicol Lett; 2001 Mar; 120(1-3):21-9. PubMed ID: 11323158
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
26. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Jordan VC
J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
[No Abstract] [Full Text] [Related]
27. [Specific estrogen receptor modulators (SERMs)].
Trémollières F; Lopes P
Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
[TBL] [Abstract][Full Text] [Related]
28. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Gajdos C; Jordan VC
Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones.
Yao D; Zhang F; Yu L; Yang Y; van Breemen RB; Bolton JL
Chem Res Toxicol; 2001 Dec; 14(12):1643-53. PubMed ID: 11743747
[TBL] [Abstract][Full Text] [Related]
30. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells.
White IN; de Matteis F; Davies A; Smith LL; Crofton-Sleigh C; Venitt S; Hewer A; Phillips DH
Carcinogenesis; 1992 Dec; 13(12):2197-203. PubMed ID: 1473224
[TBL] [Abstract][Full Text] [Related]
31. The tamoxifen dilemma.
White IN
Carcinogenesis; 1999 Jul; 20(7):1153-60. PubMed ID: 10383884
[TBL] [Abstract][Full Text] [Related]
32. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.
Hard GC; Iatropoulos MJ; Jordan K; Radi L; Kaltenberg OP; Imondi AR; Williams GM
Cancer Res; 1993 Oct; 53(19):4534-41. PubMed ID: 8402624
[TBL] [Abstract][Full Text] [Related]
33. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Sömjen D; Waisman A; Kaye AM
J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
[TBL] [Abstract][Full Text] [Related]
34. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
35. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s.
Styles JA; Davies A; Lim CK; De Matteis F; Stanley LA; White IN; Yuan ZX; Smith LL
Carcinogenesis; 1994 Jan; 15(1):5-9. PubMed ID: 8293548
[TBL] [Abstract][Full Text] [Related]
36. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
[TBL] [Abstract][Full Text] [Related]
37. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.
Curtis MG
Drug Saf; 2001; 24(14):1039-53. PubMed ID: 11735660
[TBL] [Abstract][Full Text] [Related]
38. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Dhingra K
Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
[TBL] [Abstract][Full Text] [Related]
39. Anti-implantation activity of antiestrogens and mifepristone.
Dao B; Vanage G; Marshall A; Bardin CW; Koide SS
Contraception; 1996 Oct; 54(4):253-8. PubMed ID: 8922879
[TBL] [Abstract][Full Text] [Related]
40. [Perspectives for the hormonal therapy of breast cancer].
Eckhardt S
Magy Onkol; 2003; 47(2):133-40. PubMed ID: 12975659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
